September 11, 2017, by NCI Staff
On August 30, the Food and Drug Administration (FDA) approved a type of immunotherapy called CAR T-cell therapy for certain children and young adults with a form of acute lymphoblastic leukemia (ALL). The treatment, tisagenlecleucel (Kymriah™), is the first CAR T-cell therapy to receive FDA approval.
China has a lucrative market for fake research reagents. Some scientists are fighting back.
Published in Nature | News Feature 10 May 2017
By Alan DoveSep. 14, 2017 , 2:00 PM
Commercially produced antibodies have become workhorses of basic research, but opaque supply chains, a lack of clear quality standards, and scientists’ complacency have turned antibody-based experiments into potential disaster zones. Several strategies can help researchers navigate past these pitfalls.
Clara Rodríguez Fernández on 16/01/2018
CAR-T therapy has been hailed as a cure for cancer, but what really is this miraculous technology and what can we actually expect from it?